The successful conclusion of the agreement to conduct an innovative clinical trial marks an important milestone. The trial will evaluate a potential drug for people with C9orf72-ALS—the most common genetic form of the disease.
The study’s methodological approach is particularly innovative: it is designed to accelerate the clinical evaluation of promising therapeutic approaches and shorten the path from scientific discoveries to effective treatments.
Together with our collaboration partners, we are pursuing a clear goal: to accelerate the development of new treatment options for people with ALS and to sustainably improve the outlook for those affected.
We look forward to this collaboration and the next steps on this journey.
More details about the new study will be available here soon!
ALS #ClinicalTrials #ClinicalStudies #DrugDevelopment #Innovation #Research #C9orf72 #Ulm
